NZ627111A - Variants of activin iib receptor polypeptides and uses thereof - Google Patents
Variants of activin iib receptor polypeptides and uses thereofInfo
- Publication number
- NZ627111A NZ627111A NZ627111A NZ62711109A NZ627111A NZ 627111 A NZ627111 A NZ 627111A NZ 627111 A NZ627111 A NZ 627111A NZ 62711109 A NZ62711109 A NZ 62711109A NZ 627111 A NZ627111 A NZ 627111A
- Authority
- NZ
- New Zealand
- Prior art keywords
- substitution
- polypeptide
- amino acid
- seq
- except
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 13
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 13
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 13
- 108010059616 Activins Proteins 0.000 title abstract 2
- 239000000488 activin Substances 0.000 title abstract 2
- 102000005606 Activins Human genes 0.000 title 1
- 238000006467 substitution reaction Methods 0.000 abstract 14
- 150000001413 amino acids Chemical class 0.000 abstract 8
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 4
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 abstract 2
- 108010056852 Myostatin Proteins 0.000 abstract 2
- 239000000539 dimer Substances 0.000 abstract 2
- 101710194452 Growth/differentiation factor 11 Proteins 0.000 abstract 1
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 abstract 1
- 102100026818 Inhibin beta E chain Human genes 0.000 abstract 1
- 108010023082 activin A Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20025008P | 2008-11-26 | 2008-11-26 | |
| US25906009P | 2009-11-06 | 2009-11-06 | |
| NZ604818A NZ604818A (en) | 2008-11-26 | 2009-11-24 | Variants of activin iib receptor polypeptides and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ627111A true NZ627111A (en) | 2015-10-30 |
Family
ID=41693455
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ627111A NZ627111A (en) | 2008-11-26 | 2009-11-24 | Variants of activin iib receptor polypeptides and uses thereof |
| NZ604818A NZ604818A (en) | 2008-11-26 | 2009-11-24 | Variants of activin iib receptor polypeptides and uses thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ604818A NZ604818A (en) | 2008-11-26 | 2009-11-24 | Variants of activin iib receptor polypeptides and uses thereof |
Country Status (37)
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8067562B2 (en) | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
| ES2649983T3 (es) | 2005-11-23 | 2018-01-16 | Acceleron Pharma, Inc. | Antagonistas de activina-ActRIIa en su uso para promover el crecimiento óseo |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| MX2009008222A (es) | 2007-02-01 | 2009-10-12 | Acceleron Pharma Inc | Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama. |
| TW201803890A (zh) | 2007-02-02 | 2018-02-01 | 艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| EA018221B1 (ru) | 2007-02-09 | 2013-06-28 | Акселерон Фарма Инк. | АНТАГОНИСТЫ АКТИВИНА-ActRIIa И ПРИМЕНЕНИЕ ДЛЯ СТИМУЛЯЦИИ РОСТА КОСТИ У БОЛЬНЫХ РАКОМ |
| US7947646B2 (en) | 2007-03-06 | 2011-05-24 | Amgen Inc. | Variant activin receptor polypeptides |
| US8501678B2 (en) | 2007-03-06 | 2013-08-06 | Atara Biotherapeutics, Inc. | Variant activin receptor polypeptides and uses thereof |
| CN101861161B (zh) | 2007-09-18 | 2017-04-19 | 阿塞勒隆制药公司 | 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途 |
| TW201803586A (zh) | 2008-08-14 | 2018-02-01 | 艾瑟勒朗法瑪公司 | 使用ｇｄｆ阱以增加紅血球水平 |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| JP5611222B2 (ja) | 2008-11-26 | 2014-10-22 | アムジエン・インコーポレーテツド | アクチビンｉｉｂ受容体ポリペプチドの変異体及びその使用 |
| KR20180026795A (ko) | 2009-06-12 | 2018-03-13 | 악셀레론 파마 인코포레이티드 | 절두된 ＡｃｔＲＩＩＢ-ＦＣ 융합 단백질 |
| EP3332796A1 (en) | 2009-11-17 | 2018-06-13 | Acceleron Pharma Inc. | Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| AU2011276328C1 (en) * | 2010-07-06 | 2016-01-21 | Novartis Ag | Norovirus derived immunogenic compositions and methods |
| SG187867A1 (en) | 2010-08-16 | 2013-03-28 | Amgen Inc | Antibodies that bind myostatin, compositions and methods |
| AU2011326586A1 (en) | 2010-11-08 | 2013-05-30 | Acceleron Pharma, Inc. | ActRIIA binding agents and uses thereof |
| HK1203384A1 (en) * | 2011-12-19 | 2015-12-11 | Amgen Inc. | Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof |
| NZ703724A (en) | 2012-06-11 | 2017-06-30 | Amgen Inc | Dual receptor antagonistic antigen-binding proteins and uses thereof |
| US10195249B2 (en) | 2012-11-02 | 2019-02-05 | Celgene Corporation | Activin-ActRII antagonists and uses for treating bone and other disorders |
| AU2014212014A1 (en) | 2013-02-01 | 2015-08-27 | Amgen Inc. | Administration of an anti-activin-A compound to a subject |
| US20140220033A1 (en) * | 2013-02-01 | 2014-08-07 | Santa Maria Biotherapeutics, Inc. | Administration of an Anti-Activin-A Compound to a Subject |
| TW201920262A (zh) * | 2013-07-30 | 2019-06-01 | 美商再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| CN104693270B (zh) * | 2013-12-10 | 2018-10-16 | 清华大学 | 一种用于融合蛋白的连接肽 |
| US20160333418A1 (en) * | 2014-01-14 | 2016-11-17 | Santa Maria Biotherapeutics, Inc. | Activin Inhibitor Response Prediction and Uses for Treatment |
| PE20170471A1 (es) * | 2014-06-13 | 2017-05-14 | Santa Maria Biotherapeutics Inc | Polipeptidos receptores formulados y metodos relacionados |
| CN114699529A (zh) | 2014-06-13 | 2022-07-05 | 阿塞勒隆制药公司 | 用于治疗溃疡的方法和组合物 |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| MX388739B (es) | 2015-02-06 | 2025-03-20 | Univ North Carolina Chapel Hill | Casetes optimizados de expresión del gen humano del factor viii de coagulación y su uso. |
| US10358476B2 (en) | 2015-04-06 | 2019-07-23 | Acceleron Pharma Inc. | Single arm type I and type II receptor fusion proteins and uses thereof |
| MA41920B1 (fr) | 2015-04-06 | 2021-05-31 | Acceleron Pharma Inc | Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations |
| MA41919A (fr) | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
| CA2983440C (en) | 2015-04-22 | 2024-03-12 | Alivegen Usa Inc. | Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases |
| CN116284392A (zh) | 2016-03-10 | 2023-06-23 | 艾科赛扬制药股份有限公司 | 活化素2型受体结合蛋白及其用途 |
| CA3039573A1 (en) | 2016-10-05 | 2018-04-12 | Acceleron Pharma Inc. | Alk4:actriib heteromultimers and uses thereof |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| NZ754161A (en) | 2016-11-10 | 2025-11-28 | Keros Therapeutics Inc | Activin receptor type iia variants and methods of use thereof |
| CA3082146A1 (en) | 2017-11-09 | 2019-05-16 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| IL320014A (en) | 2018-01-12 | 2025-06-01 | Keros Therapeutics Inc | Activin receptor type iib variants and methods of use thereof |
| KR20250133994A (ko) | 2018-05-09 | 2025-09-09 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법 |
| CN109320597B (zh) * | 2018-10-26 | 2021-10-26 | 中国农业科学院特产研究所 | 狐亚科激活素a蛋白及其制备与应用 |
| WO2021189010A1 (en) | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| WO2021189019A1 (en) | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Activin receptor type ii chimeras and methods of use thereof |
| US20250041385A1 (en) | 2021-12-10 | 2025-02-06 | Biogen Ma Inc. | Modified actrii proteins and methods of use thereof |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4411993A (en) | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
| USRE32011E (en) | 1981-12-14 | 1985-10-22 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| US4543439A (en) | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| DE3474511D1 (en) | 1983-11-01 | 1988-11-17 | Terumo Corp | Pharmaceutical composition containing urokinase |
| US4902614A (en) | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5567584A (en) | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
| US5750375A (en) | 1988-01-22 | 1998-05-12 | Zymogenetics, Inc. | Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions |
| JP2877509B2 (ja) | 1989-05-19 | 1999-03-31 | アムジエン・インコーポレーテツド | メタロプロテイナーゼ阻害剤 |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| US20050186593A1 (en) | 1991-05-10 | 2005-08-25 | The Salk Institute For Biological Studies | Cloning and recombinant production of CRF receptor(s) |
| US6162896A (en) | 1991-05-10 | 2000-12-19 | The Salk Institute For Biological Studies | Recombinant vertebrate activin receptors |
| US5885794A (en) | 1991-05-10 | 1999-03-23 | The Salk Institute For Biological Studies | Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily |
| US5470582A (en) | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
| US6153407A (en) | 1992-07-28 | 2000-11-28 | Beth Israel Deaconess Medical Center | Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics |
| GB9223377D0 (en) | 1992-11-04 | 1992-12-23 | Medarex Inc | Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes |
| EP0627932B1 (en) | 1992-11-04 | 2002-05-08 | City Of Hope | Antibody construct |
| US6607884B1 (en) | 1993-03-19 | 2003-08-19 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-8 |
| DK0690873T3 (da) | 1993-03-19 | 2003-09-29 | Univ Johns Hopkins Med | Vækstdifferentieringsfaktor-8 |
| US6465239B1 (en) | 1993-03-19 | 2002-10-15 | The John Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species |
| US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
| EP0756628B1 (en) | 1994-04-29 | 2007-11-14 | Curis, Inc. | Morphogenic protein-specific cell surface receptors and uses therefor |
| US6891082B2 (en) | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| US6472179B2 (en) | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| DE69936105T3 (de) | 1998-11-13 | 2017-07-27 | Immunex Corporation | Menschliche tslp nukleinsäuren und polypeptide |
| MXPA01007366A (es) | 1999-01-21 | 2002-06-04 | Metamorphix Inc | Inhibidores de factores de crecimiento y diferenciacion y usos de los mismos. |
| JP4487376B2 (ja) | 2000-03-31 | 2010-06-23 | 味の素株式会社 | 腎疾患治療剤 |
| US6812339B1 (en) * | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
| GB0209896D0 (en) | 2002-04-30 | 2002-06-05 | Molmed Spa | Conjugate |
| US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| BR0317538A (pt) | 2002-12-20 | 2005-11-29 | Amgen Inc | Agente ligante, sequência de polinucleotìdeo, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos de inibir a atividade de miostatina, de aumentar a massa muscular magra e a razão de massa muscular magra para gordura, de tratar uma doença de emaciação muscular e um distúrbio metabólico relacionado com miostatina em um indivìduo, de detectar e medir miostatina em uma amostra, e, de diagnosticar um distúrbio relacionado com miostatina em um indivìduo |
| RU2322261C2 (ru) | 2003-06-02 | 2008-04-20 | Уайт | Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний |
| US8110665B2 (en) | 2003-11-13 | 2012-02-07 | Hanmi Holdings Co., Ltd. | Pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
| ES2383300T3 (es) | 2003-11-13 | 2012-06-20 | Hanmi Holdings Co., Ltd | Fragmento Fc de IgG para un vehículo de fármacos y procedimiento para su preparación |
| JP2008507288A (ja) | 2004-07-23 | 2008-03-13 | アクセルロン ファーマ インコーポレーテッド | ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物 |
| AU2005272646A1 (en) | 2004-08-12 | 2006-02-23 | Wyeth | Combination therapy for diabetes, obesity, and cardiovascular diseases using GDF-8 inhibitors |
| WO2006036834A2 (en) | 2004-09-24 | 2006-04-06 | Amgen Inc. | MODIFIED Fc MOLECULES |
| KR100754667B1 (ko) | 2005-04-08 | 2007-09-03 | 한미약품 주식회사 | 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물 |
| NZ566774A (en) | 2005-09-07 | 2011-11-25 | Pfizer | Human monoclonal antibodies to activin receptor-like kinase-1 |
| US8067562B2 (en) | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
| WO2007105377A2 (en) * | 2006-03-02 | 2007-09-20 | Ishihara Sangyo Kaisha, Ltd. | Solid herbicidal composition |
| CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
| CN104524548A (zh) | 2006-12-18 | 2015-04-22 | 阿塞勒隆制药公司 | 活化素-actrii拮抗剂及在提高红细胞水平中的用途 |
| TW201803890A (zh) | 2007-02-02 | 2018-02-01 | 艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| US8501678B2 (en) * | 2007-03-06 | 2013-08-06 | Atara Biotherapeutics, Inc. | Variant activin receptor polypeptides and uses thereof |
| US7947646B2 (en) * | 2007-03-06 | 2011-05-24 | Amgen Inc. | Variant activin receptor polypeptides |
| ES2449753T3 (es) * | 2007-03-19 | 2014-03-21 | National Research Council Of Canada | Proteínas de fusión que comprenden dos dominios de unión tgf-beta |
| CN101861161B (zh) | 2007-09-18 | 2017-04-19 | 阿塞勒隆制药公司 | 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途 |
| KR20100090683A (ko) | 2007-11-09 | 2010-08-16 | 제넨테크, 인크. | 액티빈 수용체-유사 키나제-ｉ 길항제 조성물 및 사용 방법 |
| CN102131822A (zh) | 2008-06-26 | 2011-07-20 | 阿塞勒隆制药公司 | 进行激活素-ActRIIa拮抗剂给药和监测受治疗患者的方法 |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| TW201803586A (zh) | 2008-08-14 | 2018-02-01 | 艾瑟勒朗法瑪公司 | 使用ｇｄｆ阱以增加紅血球水平 |
| JP5611222B2 (ja) | 2008-11-26 | 2014-10-22 | アムジエン・インコーポレーテツド | アクチビンｉｉｂ受容体ポリペプチドの変異体及びその使用 |
| AU2010204985A1 (en) | 2009-01-13 | 2011-08-04 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
| PE20120532A1 (es) | 2009-04-27 | 2012-05-18 | Novartis Ag | ANTICUERPOS ANTI-ActRIIB |
| KR20120049214A (ko) | 2009-06-08 | 2012-05-16 | 악셀레론 파마 인코포레이티드 | 발열성 지방세포를 증가시키는 방법 |
| US20120295814A1 (en) | 2010-01-08 | 2012-11-22 | The Brigham And Women's Hospital, Inc. | CA-125 Immune Complexes as Biomarkers of Ovarian Cancer |
| WO2011123691A1 (en) | 2010-03-31 | 2011-10-06 | Keryx Biopharmaceuticals, Inc. | Perifosine and capecitabine as a combined treatment for cancer |
| AU2011326586A1 (en) | 2010-11-08 | 2013-05-30 | Acceleron Pharma, Inc. | ActRIIA binding agents and uses thereof |
| WO2013106715A1 (en) | 2012-01-13 | 2013-07-18 | Allergan, Inc. | Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation |
| WO2013180295A1 (ja) | 2012-06-01 | 2013-12-05 | 日本電信電話株式会社 | パケット転送処理方法およびパケット転送処理装置 |
| US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
-
2009
- 2009-11-24 JP JP2011538599A patent/JP5611222B2/ja not_active Expired - Fee Related
- 2009-11-24 HR HRP20161450TT patent/HRP20161450T1/hr unknown
- 2009-11-24 NZ NZ627111A patent/NZ627111A/en not_active IP Right Cessation
- 2009-11-24 UA UAA201107872A patent/UA107921C2/ru unknown
- 2009-11-24 SG SG10201703067QA patent/SG10201703067QA/en unknown
- 2009-11-24 CA CA2997971A patent/CA2997971A1/en not_active Abandoned
- 2009-11-24 BR BRPI0920962A patent/BRPI0920962A2/pt not_active IP Right Cessation
- 2009-11-24 MY MYPI2011002346A patent/MY159483A/en unknown
- 2009-11-24 AR ARP090104527A patent/AR074397A1/es not_active Application Discontinuation
- 2009-11-24 CN CN200980147945.3A patent/CN102245634B/zh not_active Expired - Fee Related
- 2009-11-24 LT LTEP09761055.4T patent/LT2370463T/lt unknown
- 2009-11-24 RS RS20160909A patent/RS55369B1/sr unknown
- 2009-11-24 EA EA201100832A patent/EA201100832A1/ru unknown
- 2009-11-24 HU HUE09761055A patent/HUE032090T2/en unknown
- 2009-11-24 KR KR1020177007651A patent/KR101778134B1/ko not_active Expired - Fee Related
- 2009-11-24 KR KR1020177025044A patent/KR20170105124A/ko not_active Abandoned
- 2009-11-24 CR CR20160443A patent/CR20160443A/es unknown
- 2009-11-24 DK DK09761055.4T patent/DK2370463T3/en active
- 2009-11-24 KR KR1020117014720A patent/KR101720143B1/ko not_active Expired - Fee Related
- 2009-11-24 PT PT97610554T patent/PT2370463T/pt unknown
- 2009-11-24 NZ NZ604818A patent/NZ604818A/en not_active IP Right Cessation
- 2009-11-24 WO PCT/US2009/006252 patent/WO2010062383A2/en not_active Ceased
- 2009-11-24 CN CN201410462932.8A patent/CN104371024A/zh active Pending
- 2009-11-24 PL PL09761055T patent/PL2370463T3/pl unknown
- 2009-11-24 EP EP16179980.4A patent/EP3101029B1/en active Active
- 2009-11-24 EA EA201791940A patent/EA201791940A3/ru unknown
- 2009-11-24 PE PE2015000401A patent/PE20150680A1/es not_active Application Discontinuation
- 2009-11-24 MA MA33960A patent/MA32936B1/fr unknown
- 2009-11-24 ES ES09761055.4T patent/ES2600491T3/es active Active
- 2009-11-24 EP EP09761055.4A patent/EP2370463B1/en active Active
- 2009-11-24 AU AU2009320364A patent/AU2009320364B2/en not_active Ceased
- 2009-11-24 SG SG2011037777A patent/SG171813A1/en unknown
- 2009-11-24 PE PE2011001077A patent/PE20120206A1/es not_active Application Discontinuation
- 2009-11-24 MX MX2011005505A patent/MX2011005505A/es active IP Right Grant
- 2009-11-24 SI SI200931546A patent/SI2370463T1/sl unknown
- 2009-11-24 CA CA2743850A patent/CA2743850C/en not_active Expired - Fee Related
- 2009-11-24 ME MEP-2016-243A patent/ME02652B/me unknown
- 2009-11-25 US US12/626,375 patent/US8410043B2/en active Active
- 2009-11-26 TW TW098140431A patent/TWI486166B/zh not_active IP Right Cessation
-
2011
- 2011-05-08 IL IL212773A patent/IL212773A/en not_active IP Right Cessation
- 2011-05-12 TN TN2011000238A patent/TN2011000238A1/fr unknown
- 2011-05-26 CL CL2011001239A patent/CL2011001239A1/es unknown
- 2011-06-23 CO CO11079058A patent/CO6382163A2/es not_active Application Discontinuation
- 2011-06-23 ZA ZA2011/04648A patent/ZA201104648B/en unknown
- 2011-06-24 CR CR20110364A patent/CR20110364A/es unknown
-
2013
- 2013-02-25 US US13/775,756 patent/US9273114B2/en active Active
-
2014
- 2014-09-02 JP JP2014177598A patent/JP5969557B2/ja not_active Expired - Fee Related
-
2016
- 2016-01-22 US US15/004,375 patent/US10308704B2/en active Active
- 2016-07-07 JP JP2016134684A patent/JP2016199577A/ja not_active Ceased
- 2016-09-29 IL IL248128A patent/IL248128A0/en unknown
- 2016-11-16 CY CY20161101175T patent/CY1118754T1/el unknown
- 2016-11-16 SM SM201600417T patent/SMT201600417B/it unknown
-
2019
- 2019-04-18 US US16/388,561 patent/US11685770B2/en active Active
-
2023
- 2023-06-07 US US18/206,963 patent/US20230295267A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ627111A (en) | Variants of activin iib receptor polypeptides and uses thereof | |
| NZ609216A (en) | Anticancer fusion protein | |
| IL199263A (en) | Glucagon peptide with enhanced solubility, pharmaceutical composition containing it and its uses for drug preparation | |
| WO2007115837B1 (en) | Combination of an anti-edb fibronectin domain antibody/ il2 fusion protein and a further small molecule | |
| EP2476699A3 (en) | Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides | |
| EP2594582A3 (en) | Peptide vaccines with Seq Id No: 110, 111, 387, 112, 394 114, 116, 117 or 121 for cancers expressing tumor-associated antigens | |
| NZ602943A (en) | Modified binding proteins inhibiting the vegf-a receptor interaction | |
| UA103774C2 (uk) | Модифіковані поліпептиди бичачого гранулоцитарного колонієстимулювального фактора (g-csf) та їх застосування | |
| WO2013080147A3 (en) | Anticancer fusion protein | |
| PE20130615A1 (es) | Polipeptidos del receptor de activina variante y uso de los mismos | |
| UA103216C2 (uk) | Поліпептид з ксиланазною активністю | |
| NZ603623A (en) | Tcr complex immunotherapeutics | |
| NZ602170A (en) | Modified leptin polypeptides and their uses | |
| WO2009004315A8 (en) | Isolated peptides and uses thereof | |
| MX2008009493A (es) | Peptido novedoso y uso del mismo. | |
| UA100127C2 (ru) | Пептид cdh3 и лекарственное средство, содержащее его | |
| WO2006090810A3 (en) | Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides | |
| MX2014008028A (es) | Proteina de fusion anticancerigena. | |
| WO2010007144A3 (en) | Mutated netrin-4 proteins, fragments thereof and their uses as drugs | |
| WO2011135222A3 (fr) | Utilisation de peptides comme transporteurs destines a l'internalisation de molecules d'interet dans des cellules cibles | |
| MX2009000918A (es) | Derivados de citocina. | |
| WO2008047370A3 (en) | Compositions and methods for inducing angiogenesis | |
| ATE552271T1 (de) | Antitumorarzneimittel, medikament, zusammensetzung und anwendung davon | |
| ATE441865T1 (de) | Neue polypeptide zur in-vintro-isolierung und vorbeugung von infektionen mit legionella pneumophila | |
| WO2013038385A3 (en) | Escherichia coli vaccine combination |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 24 NOV 2016 BY FB RICE Effective date: 20160308 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 NOV 2017 BY CPA GLOBAL Effective date: 20161014 |
|
| LAPS | Patent lapsed |